NCT04060511View on ClinicalTrials.gov

A Study of HS-10342 in Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

December 4, 2020

Study Completion Date

September 15, 2021

Conditions
Advanced Solid Tumor
Interventions
DRUG

HS-10342

HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID

Trial Locations (5)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

210029

Jiangsu Province Hospital, Nanjing

450003

Henan Cancer Hospital, Zhengzhou

510080

Sun Yat-sen University Cancer Hospital, Guangzhou

510120

Second Affiliated Hospital of Sun Yat-sen University, Guangzhou

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY